Release Date: October 2007

Valid Through: October 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following:

Updates on the Management of Advanced Hepato-pancreato-biliary Malignancies: A Report from the 14th The European Cancer Conference (ECCO) 

Author: Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

Dr. Ghassan Abou-Alfa is a medical oncologist at the Memorial Sloan-Kettering Cancer Center, New York, NY. Dr. Abou-Alfa specializes in the treatment of gastrointestinal cancers; pancreas, gall bladder, and bile duct tumors; and primary liver cancer. In an effort to improve the effectiveness of cancer therapy, he is also focused on working to incorporate small biological molecules that target cancer therapy into the treatment regimen for chemotherapy-resistant gastrointestinal malignancies, specifically pancreatic and hepatobiliary cancers.

Dr. Abou-Alfa has authored or co-authored many medical publications in peer-reviewed journals, including the Journal of Clinical Oncology, Seminars in Oncology, Cancer and other peer-reviewed journals.

 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Consider the clinical impact of emerging therapies on survival and quality of life for hepatocellular carcinoma and pancreatic cancer.
• Evaluate orally presented hepato-pancreato-biliary data based on study design, the reported results, and authors’ conclusions.
• Consider the reviewed data as it relates to previous, concurrent and future treatment of hepatocellular carcinoma and pancreatic cancer.
• Categorize side effects and safety profiles of emerging therapies for hepatocellular carcinoma and pancreatic cancer.
  

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an unrestricted educational grant provided by Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals.